HOWL News

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. Upon closing of the proposed transaction, Werewolf shareholders are expected to own approximately 6.8% of the combined company.Halper Sadeh...

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC PR Newswire NEW YORK, Aug. 23, 2026 NEW YORK, Aug. 23, 2026 /PRNewswire...

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences (NASDAQ:JUNS)read more...

Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.read more...

Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...

Biotech mergers can completely remake small public companies overnight, particularly when a transaction brings together a late-stage clinical asset, institutional capital and a clear regulatory path. Add an orphan disease with no FDA-approved drug therapy, and investors suddenly have a very different company to value than the one that existed the day before.Shares of Werewolf Therapeutics, Inc. (Nasdaq: HOWL) are soaring Friday after the immuno-oncology company announced a definitive all-stock merger with privately held Ambros Therapeutics alongside an oversubscribed $150 million private ...

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.read more...

Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.read more...

Werewolf Therapeutics (NASDAQ:HOWL) is effectively rewriting its investment story. The company has agreed to merge with privately held Ambros Therapeutics in an all-stock transaction that will bring late-stage drug candidate neridronate into a Nasdaq-listed vehicle, while simultaneously securing an oversubscribed $150 million private placement from a heavyweight group of healthcare investors. The combined company is expected to operate as Ambros Therapeutics and trade under NASDAQ:AMBX, subject to closing conditions.